E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

The Wnt/β-catenin signaling pathway plays crucial roles in embryonic development and the development of multiple types of cancer, and its aberrant activation provides cancer cells with escape mechanisms from immune checkpoint inhibitors. E7386, an orally active selective inhibitor of the interaction...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2021-02, Vol.81 (4), p.1052-1062
Main Authors: Yamada, Kazuhiko, Hori, Yusaku, Inoue, Satoshi, Yamamoto, Yuji, Iso, Kentaro, Kamiyama, Hiroshi, Yamaguchi, Atsumi, Kimura, Takayuki, Uesugi, Mai, Ito, Junichi, Matsuki, Masahiro, Nakamoto, Kazutaka, Harada, Hitoshi, Yoneda, Naoki, Takemura, Atsushi, Kushida, Ikuo, Wakayama, Naomi, Kubara, Kenji, Kato, Yu, Semba, Taro, Yokoi, Akira, Matsukura, Masayuki, Odagami, Takenao, Iwata, Masao, Tsuruoka, Akihiko, Uenaka, Toshimitsu, Matsui, Junji, Matsushima, Tomohiro, Nomoto, Kenichi, Kouji, Hiroyuki, Owa, Takashi, Funahashi, Yasuhiro, Ozawa, Yoichi
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
beta Catenin - antagonists & inhibitors
beta Catenin - metabolism
Cell Proliferation - drug effects
Cells, Cultured
Disease Models, Animal
Female
Genes, APC
HEK293 Cells
Humans
Mice
Mice, Inbred C57BL
Mice, Nude
Mice, Transgenic
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Peptide Fragments - antagonists & inhibitors
Peptide Fragments - metabolism
Protein Binding - drug effects
Sialoglycoproteins - antagonists & inhibitors
Sialoglycoproteins - metabolism
Wnt Signaling Pathway - drug effects
Wnt Signaling Pathway - genetics
Wnt1 Protein - genetics
Wnt1 Protein - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Wnt/β-catenin signaling pathway plays crucial roles in embryonic development and the development of multiple types of cancer, and its aberrant activation provides cancer cells with escape mechanisms from immune checkpoint inhibitors. E7386, an orally active selective inhibitor of the interaction between β-catenin and CREB binding protein, which is part of the Wnt/β-catenin signaling pathway, disrupts the Wnt/β-catenin signaling pathway in HEK293 and adenomatous polyposis coli ( )-mutated human gastric cancer ECC10 cells. It also inhibited tumor growth in an ECC10 xenograft model and suppressed polyp formation in the intestinal tract of mice, in which mutation of activates the Wnt/β-catenin signaling pathway. E7386 demonstrated antitumor activity against mouse mammary tumors developed in mouse mammary tumor virus (MMTV)-Wnt1 transgenic mice. Gene expression profiling using RNA sequencing data of MMTV-Wnt1 tumor tissue from mice treated with E7386 showed that E7386 downregulated genes in the hypoxia signaling pathway and immune responses related to the CCL2, and IHC analysis showed that E7386 induced infiltration of CD8 cells into tumor tissues. Furthermore, E7386 showed synergistic antitumor activity against MMTV-Wnt1 tumor in combination with anti-PD-1 antibody. In conclusion, E7386 demonstrates clear antitumor activity via modulation of the Wnt/β-catenin signaling pathway and alteration of the tumor and immune microenvironments, and its antitumor activity can be enhanced in combination with anti-PD-1 antibody. SIGNIFICANCE: These findings demonstrate that the novel anticancer agent, E7386, modulates Wnt/β-catenin signaling, altering the tumor immune microenvironment and exhibiting synergistic antitumor activity in combination with anti-PD-1 antibody.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-20-0782